Statistics

Total Visits

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer7

Select a period of time:

Number of views in the range

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer3

Views

Views
May 20240
June 20240
July 20241
August 20241
September 20241
October 20240
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States3
 

Top cities views

Views
Chicago1